

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 004 880 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
31.05.2000 Bulletin 2000/22

(51) Int. Cl.⁷: **G01N 33/50**, G01N 33/58,
G01N 33/52

(21) Application number: 98310004.1

(22) Date of filing: 07.12.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 27.11.1998 JP 33691698

(71) Applicant: Sysmex Corporation
Kobe-shi, Hyogo 651-0073 (JP)

(72) Inventors:
• Tsuji, Tomohiro
Himeji-shi, Hyogo (JP)

• Sakata, Takashi
Kakogawa-shi, Hyogo (JP)
• Ikeuchi, Yoshiro
Himeji-shi, Hyogo (JP)
• Oguni, Shin'ichiro
Kobe-shi, Hyogo (JP)

(74) Representative:
Paget, Hugh Charles Edward et al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

(54) Erythroblast diagnostic flow-cytometry method and reagents

(57) Reagents and a method for simple and rapid discrimination and counting of erythroblasts in peripheral blood or circulatory system-related samples accurately with high precision is disclosed. The reagents include a hemolytic agent for dissolving erythrocytes in a body fluid sample and for conditioning leukocytes and erythroblasts in the sample to be suitable for staining, and including at least one fluorescent dye selected to stain leukocytes and erythroblasts differentially. When the selected fluorescent dye is mixed with the sample, a detectable difference in fluorescence intensity at least between leukocytes and erythroblasts arises under laser illumination in flow cytometric analysis. The reagents further include surfactant added to the hemolytic agent, selected to enable flow cytometric discrimination of erythroblasts in the body fluid sample by their maturation stages.

Description

BACKGROUND OF THE INVENTION

5 Technical Field

[0001] The present invention relates to flow-cytometric diagnosis of formed elements of blood; in particular the invention relates to discrimination and counting of erythroblasts from peripheral blood or other body fluid samples by flow cytometry.

10

Description of Related Art

[0002] In the field of clinical examination, sorting and counting of erythroblasts can yield vital information in the diagnosis of disease.

15 [0003] Erythropoiesis is a process of the bone marrow, and normally erythroblasts, prior to their release into circulation as reticulocytes in the final stage of maturation into red blood cells, are not present in the peripheral blood. Consequently, the appearance in the peripheral blood of erythroblasts in any of the distinguishable erythropoietic stages prior to becoming reticulocytes indicates the possibility of the presence of disease, such as acute myelocytic leukemia, hemolytic anemia, iron deficiency anemia and pernicious anemia. Accordingly, erythroblast sorting and counting can

20 be extremely useful in diagnosing these sorts of diseases.

[0004] Conventionally in counting and sorting erythroblasts, generally blood smears are prepared which are then suitably stained for counting and sorting through microscopic observation.

[0005] On the other hand, various fully automated leukocyte sorter/counter devices that apply flow cytometric principles are available. "Flow Cytometers - History and Measurement Principle," *Sysmex Journal International*, Vol. 6 No. 1 (1996) is an introduction to flow cytometry as applicable to the present invention, and is herein incorporated by reference.

25 [0006] Wherein erythroblasts have appeared in the peripheral blood, however, results output from flow cytometric devices and analyzed diagrammatically only suggest, by abnormal "flags," (indicating unusual plots from the flow cytometric data) the possibility of the presence of erythroblasts, and do not enable accurate erythroblast sorting/counting. Such flags often turn out to be false positive results.

30 [0007] Furthermore, apart from the foregoing, Japanese Laid-Open Pat. No. 4-268453 (1992), and U.S. Pat. No. 5,559,037 disclose erythroblast sorting/counting methods.

[0008] Either of these are methods by which erythroblasts are assayed by treating samples with a suitable hemolytic agent that disables only cell membranes of erythrocytes (confers dye permeability to the cell membranes) and with a solvent that does not injure cell membranes of leukocytes (does not confer dye permeability to the cell membranes), and afterwards (or at the same time) staining with a fluorescent dye only the erythroblasts whose cell membranes have been damaged, then discriminating erythroblasts from leukocytes by measuring fluorescence intensity.

35 [0009] Wherein fresh blood is used immediately after the sample is taken, accurate measurements are possible with these methods. With the elapse of time after a blood sample is taken, however, not only erythroblast but also leukocyte cell membranes are easily injured, and a likely portion of the leukocytes will get stained by the fluorescent dye because their cell membranes have been damaged prior to the mixing in of hemolytic agent. There is a problem in particular wherein lymphocyte cells are injured, in that it is difficult to discriminate injured lymphocytes distinctly from erythroblasts, such that erythroblasts cannot be sorted and counted accurately.

40 [0010] With some samples in which lymphoblasts appear, which are close in size to erythroblasts, or with samples from chemotherapy patients in which cell membranes of leukocytes are liable to be disabled by the hemolytic agent, accurate erythroblast counting/sorting is difficult even right after the blood is drawn.

SUMMARY OF THE INVENTION

50 [0011] An object of the present invention is to discriminate and count erythroblasts in peripheral blood or circulatory system-related samples accurately with high precision, even with samples wherein post-sample draw time has elapsed, or wherein easily damaged leukocytes are present.

[0012] The present invention provides reagents for discriminating and counting erythroblasts, including a hemolytic agent for dissolving erythrocytes in a body fluid sample and for conditioning leukocytes and erythroblasts in the sample to be suitable for staining, and including at least one fluorescent dye selected to stain leukocytes and erythroblasts differentially. When the selected fluorescent dye is mixed with the sample, a detectable difference in fluorescence intensity at least between leukocytes and erythroblasts arises under laser illumination in flow cytometric analysis.

55 [0013] The reagents provided by the present invention further include surfactant added to the hemolytic agent,

selected to enable flow cytometric discrimination of erythroblasts in the body fluid sample by their maturation stages.

[0014] Furthermore, the present invention is a method of flow-cytometrically assaying body fluid samples utilizing reagents as mentioned above to discriminate and count erythroblasts in the samples.

[0015] The method includes the preparatory steps of: (a) mixing the body fluid sample with a hemolytic agent selected for dissolving erythrocytes within body fluid samples to an extent that does not interfere with the flow-cytometric assay, and for conditioning leukocytes and erythroblasts in the assay sample to be suitable for staining, and (b) staining leukocytes and erythroblasts in the sample as prepared in said step (a) by mixing the sample with at least one of the fluorescent dyes selected to stain leukocytes and erythroblasts differentially; and the method further includes the steps of: (c) flow cytometrically assaying the sample as prepared in said step (b) by measuring at least one scattered light parameter and at least one fluorescence parameter, and (d) discriminating and counting erythroblasts utilizing intensity differences in scattered light and in fluorescence as measured in step (c).

[0016] The foregoing and other objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017]

Fig. 1 is an example of a red fluorescence intensity/low-angle forward scatter intensity scattergram for a blood sample assayed utilizing the method of the present invention;

Figs. 2-6 are red fluorescence intensity/low-angle forward scatter intensity scattergrams, each of a blood sample from a patient in whom erythroblasts had appeared in the peripheral circulation, and each assayed with the respective reagents of Examples 1-5;

Fig. 7 is a diagram correlating results measured in accordance with the method of the present invention, with results obtained manually by microscopic observation.

Fig. 8 is likewise a red fluorescence intensity/low-angle forward scatter intensity scattergram of a blood sample from a patient in whom erythroblasts had appeared in the peripheral circulation, assayed with the reagent of Example 6, demonstrating discrimination of erythroblasts into three maturation stage populations; and

Fig. 9 is a drawing corresponding to Fig. 8, diagramming the blood cell populations discriminated from the sample with the Example 6 reagent.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Assay samples in the present invention are body fluids containing leukocytes and erythroblasts, and as such include samples from the blood peripheral circulation, bone marrow fluid, urine or samples obtained via apheresis.

[0019] A method for discriminating and counting erythroblasts in accordance with the present invention, employs a hemolytic agent selected for dissolving erythrocytes in body fluid sample to an extent such that the hemolytic agent does not interfere with flow cytometric assay, and for conditioning leukocytes and erythroblasts in the body fluid sample to be suitable for staining.

[0020] A suitable hemolytic agent is, for example, an aqueous solution having a pH of about 2.0 to 5.0 and an osmotic pressure of about 100 mOsm/kg or less. Such a hemolytic agent according to the invention further may contain surfactant in a concentration in the range of 10 to 10,000 mg/l.

[0021] Principal objects of the inventive method are to dissolve erythrocytes, which ordinarily are present in a concentration 1000 times that of leukocytes and interfere with assaying of erythroblasts, and to stain body fluid sample leukocytes and erythroblasts differentially, wherein said fluorescent dye is selected to produce a difference detectable by flow cytometry in fluorescence intensity between the leukocytes and erythroblasts.

[0022] Although there are slight individual differences, ordinarily rupturing will occur in the cell membranes of erythrocytes in solution at an osmotic pressure of 150 mOsm/kg or less, and the intracellular hemoglobin will flow out (i.e., hemolysis occurs), such that the cells become optically transparent "ghosts." Optically transparent erythrocytes accordingly do not hinder assaying of leukocytes and erythroblasts. Hemolysis proceeds even faster the lower the osmotic pressure and pH value of the solution, and the greater the amount of surfactant. Taking into consideration individual differences in erythrocytes, in the present invention the hemolytic agent is employed at an osmotic pressure of 100 mOsm/kg or less. To achieve this osmotic pressure, the hemolytic agent can be adjusted by an electrolyte such as NaCl or KCl, a sugar or a buffer as described below.

[0023] Wherein the pH is too low, not only erythrocytes but also leukocytes and erythroblasts are subject to excessive hindrance, and therefore it becomes difficult to obtain a below-described analyzable difference in fluorescence intensity.

[0024] In order that erythrocytic hemolysis be carried out efficiently, it is preferable that the pH be in the acidic end.

Especially preferable is a pH of 2.0 - 5.0, and more preferably a pH of 2.5 - 4.5 is selected.

[0025] Likewise, excessively high surfactant concentration in the hemolytic agent handicaps flow cytometric assay based on the below described difference in fluorescence intensity, not only of erythrocytes, but also of leukocytes and erythroblasts.

5 [0026] In order to enable counting and discriminating of erythroblasts by maturation stage, it is suitable to make the concentration of surfactant 10 - 10,000 mg/l. It is more suitable to select a concentration of about 100 - 5,000 mg/l. This accordingly enables sorting of the maturation stages present in the erythroblast population into at least two groups.

[0027] It is preferable to use a buffer to maintain the solution at constant pH, and a buffer having a pK_a that sets the pH in the vicinity of ± 2.0 can be employed. For example the buffer can be selected from citric acid, malic acid, diglycolic acid, and malonic acid.

10 [0028] Furthermore, a hemolytic agent which contains intramolecularly at least either an organic acid having at least one aromatic ring, or its salt, dissolves erythrocytes more efficiently (i.e., in a shorter period of time). Examples of a preferable organic acid or its salt include salicylic acid, sodium salicylate and phthalic acid.

[0029] Under these conditions, rupturing of the cell membrane and hemolysis of erythroblasts will also occur likewise as with erythrocytes, however, properties of the erythroblast nuclei nearly the same as those of living cells are retained.

[0030] On the other hand, damage to leukocyte cell membranes is not definite, and optically under microscopic observation no notable difference from living cells could be recognized.

20 [0031] A preferable hemolytic agent for the present invention dissolves erythrocytes at hypotonic osmotic pressure and contains a dissolve-resistant dye solublizer, and surfactant for the purpose of preventing ghost erythrocyte agglutination, preventing platelet agglutination and for promoting ghost shrinkage and erythrocytic hemolysis.


[0032] As noted above, the presence of a great quantity of surfactant in the hemolytic agent is a problem, in particular because excess surfactant changes erythroblast nuclear properties and lessens the difference in fluorescence intensity between erythroblasts and leukocytes as defined below.

25 [0033] Consequently for the hemolytic agent employed in the present invention, the surfactant is adjusted so as not to lessen the difference in fluorescence intensity between erythroblasts and leukocytes, and distinct from conventional hemolytic agents, the surfactant does not contain ingredients that dissolve cell components.

[0034] The foregoing conditions for the flow-cytometric assaying reagents and method of the present invention, unanticipatedly gave rise to a distinct difference, conventionally considered impossible, in fluorescence intensity between erythroblasts and leukocytes, and furthermore enabled the discrimination and counting of erythroblasts by maturation stage.

30 [0035] For discriminating and counting erythroblasts in body fluid samples by flow cytometry in accordance with the present invention, at least one fluorescent dye is employed, from the following selected group:

35 [Chem. 1]




45 wherein R_1 , R_2 are either a hydrogen molecule, an alkyl group, an alkynyl group or an alkyl group substituted with a hydroxyl, Y, Z are either sulfur, oxygen, nitrogen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;

50


55

[Chem. 2]




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 and R_3 are a hydrogen molecule, a lower alkyl group or a lower alkoxy group, R_4 is a hydrogen molecule, an acyl group or an alkyl group, Z is sulfur, oxygen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;

[Chem. 3]




wherein R_1 is a hydrogen molecule or a dimethylamino group, R_2 is an alkyl group, R_3 is a hydrogen molecule or a dimethylamino group, n is 1 or 2, and X^- is an anion;

[Chem. 4]




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 is a dimethylamino group, R_3 is a hydrogen molecule or an amino group, R_4 is a hydrogen molecule, an alkyl group or an amino group, R_5 is a hydrogen molecule or a dimethylamino group, X^- is an anion, and Y is sulfur or oxygen;

[Chem. 5]




wherein R_1 is a hydrogen molecule or a hydroxyl, R_2 , R_3 are a hydrogen molecule or a sulfonic group, and Y^+ is an alkali metal ion;

[Chem. 6]




NK-2825;

[Chem. 7]




NK-1836;

[Chem. 8]



NK-1954;


[Chem. 9]



Oxazine 750;

[Chem. 10]

5




10

Cryptocyanine;

[Chem. 11]

15




20

NK-376;

[Chem. 12]

25




30

NK-382;

[Chem. 13]

35




40

NK-2711;

[Chem. 14]

45




50

NK-138;


55

[Chem. 15]




Oxazine 720;

[Chem. 16]




LDS730;

[Chem. 17]




LD700;

[Chem. 18]




Nile Blue A;

[Chem. 19]




Brilliant Green;

[Chem. 20]



Iodine Green; and

[Chem. 21]



Malachite Green.

In general in the foregoing formulae, examples of an alkyl group bound to a nitrogen atom in a hetero-ring or a carbon atom that can be given are: alkyl groups having 1-20 carbons, preferably 1-10 carbons, or more preferably 1-6 carbons; for instance, methyl, ethyl, propyl, butyl, pentyl and hexyl. The lower alkyl groups or lower alkoxy groups are straight-chain or branched alkyl or alkoxy groups of 1-8 carbons, and preferably are methyl, ethyl, methoxy, or ethoxy. As acyl groups those of 1-3 carbons are preferable; for example, formyl, acetyl or propionyl. Preferable anions include halogens such as F⁻, Cl⁻, Br⁻, as well as I⁻ and CF₃SO₃⁻, BF₄⁻ and ClO₄⁻.

[0036] Among the dyes recited in the foregoing, the NK series are from Nippon Kando Shikiso Kenkyusho Co., Ltd., and LDS730 and LD700 are from Exciton Inc.; the others are products that can be purchased commercially.

[0037] The selected fluorescent dye may be dissolved in the hemolytic agent, and made to act on the body fluid sample simultaneously with the hemolytic agent (and can be mixed with the hemolytic agent), or it may be added to the sample after a dissolving process (step thereof) in a proper solvent (water, lower alcohol, ethylene glycol, DMSO, etc.)


[0038] Although the concentration of the fluorescent dye differs depending on the dye used, it is generally in the range of 0.01 to 100 mg/l, preferably 0.1 to 10 mg/l and more preferably 0.3 to 3.0 mg/l. These concentrations are for the state in which the dye solution is mixed with the hemolytic agent.

[0039] Wherein blood cells in the sample treated with the foregoing hemolytic agent were stained with the above-mentioned dye, leukocytes stained strongly and emitted an intense fluorescence when measured by the flow cytometer. On the other hand, erythroblasts stained weakly and emitted a faint fluorescence. The mechanism acting to give rise to the difference in fluorescence intensity between leukocytes and erythroblasts is not clear, however, it is thought that the

taking up of the dye into the erythroblast nucleus is inhibited because the nucleus (DNA) is condensed.


[0040] As surfactants enabling discrimination and counting of erythroblasts into each of the erythroblast maturation stages, at least one kind among the surfactants from the group below is used.

[Chem. 22]




wherein R_1 , R_2 and R_3 either identically or differently are hydrogen atoms, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_4 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and X^- is an anion;

[Chem. 23]




wherein R_1 is a C_{8-18} alkyl group, and X^- is an anion;

[Chem. 24]



wherein R_1 , R_2 either identically or differently are hydrogen atoms, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_3 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and n is 1 or 2;




[Chem. 25]

wherein R_1 is a C_{9-25} alkyl group, alkenyl group or alkynyl group, R_2 is $-O-$,




or $-COO-$, and n is 10 to 40;

[Chem. 26]




"MEGA-8";

[Chem. 27]




sucrose monocaprate;

[Chem. 28]




"Deoxy-BIGCHAP";

[Chem. 29]




n-octyl- β -D-thioglucoside

[Chem. 30]




n-nonyl- β -D-thiomaltoside;

[Chem. 31]




n-heptyl- β -D-thioglucoside;

[Chem. 32]




n-octyl- β -D-thioglucoside;

[Chem. 33]



"CHAPS"; and

[Chem. 34]



"CHAPSO."

[0041] In general in the foregoing formulae, octyl, heptyl, hexyl and benzyl can be cited as examples of C_{1-8} alkyl groups or C_{6-8} aralkyl groups. A C_{1-3} alkyl group such as methyl or ethyl is preferable.

[0042] Octyl and benzyl can be given as examples of C_{8-18} alkyl groups and C_{8-18} alkenyl groups. C_{10-18} straight-chain alkyl groups such as decyl, dodecyl and tetradecyl are preferable.

[0043] Decyl, dodecyl and tetradecyl can be given as examples of straight-chain C_{8-18} alkyl groups. Nonyl, dodecyl, hexadecyl and oeryl can be given as examples of C_{9-25} alkyl groups, alkenyl groups or alkynyl groups.

[0044] Among the above-recited surfactants, those listed from "MEGA-8" to CHAPSO" can be purchased from Dojindo Laboratories.

[0045] The concentration of surfactant is 10-10,000 mg/l, preferably 100-5000 mg/l, and more preferably 1000-3000 mg/l. These concentrations are of surfactant as contained in the hemolytic agent.

[0046] In a preferable mode of the present invention, a reagent of simple composition can be utilized, obtained by dissolving an organic acid such as salicylic acid, a dye, and a surfactant in purified water, and adjusting the pH using NaOH, HCl or the like. Samples are mixed with the reagent and reacted at 15-50 °C, preferably 20-40 °C for a 3-120 second period, preferably a 5-40 second period.

[0047] The accordingly prepared assay sample is analyzed with the flow cytometer, measuring at least one scattered light parameter and at least one fluorescence parameter.

[0048] A scattered light parameter according to the present invention designates scattered light which can be measured by the general commercial flow cytometer, and can be low-angle forward scattered light (for example, wherein the received light angle is in the vicinity of 0 - 5 degrees) and a high-angle forward scattered light (for example, wherein the received light angle is in the vicinity of 5 - 20 degrees), or orthogonal/side scattered light. Preferably, a scattering angle that reflects leukocyte size information is chosen. Herein, low-angle forward scattered light is preferable.

[0049] Fluorescence as a parameter in the present invention is light emitted by dye bound to the above-described cell components, and a suitable received light wavelength is selected depending on the dye used. The fluorescent signal reflects the cytochemical characteristics of the cells.

[0050] The light source of the flow cytometer is not particularly limited; a light source of wavelength suitable to excite the dye is selected. For example, an argon-ion laser, a He-Ne laser or a red semiconductor laser can be used. The semiconductor laser is especially preferable, being quite inexpensive compared with gas lasers, making it possible to lower the costs of the device considerably.

- [0051] Utilizing measured scattered light and difference in fluorescence intensity, erythroblasts are discriminated from the assay sample and counted; further erythroblasts are discriminated and counted by maturation stage. In the present invention, a process of utilizing measured scattered light and difference in fluorescence intensity to discriminate erythroblasts from the assay sample and count the discriminated erythroblasts is a process of: (1) wherein the scattergram is for example drawn taking the X-axis for low-angle forward scattered light and the Y-axis for fluorescence, as shown for instance in Fig. 1, distributing the cells by forming them into erythroblast (NRBC), leukocyte (WBC) and hemoglobin-depleted erythrocyte (Ghost) populations (i.e., clusters); then (2) using suitable analyzing software, setting these populations into population regions, and by analyzing counts of cells contained within these regions, computing the number and proportion of erythroblasts. Further, in the present invention a process of discriminating and counting erythroblasts by maturation stage is a process of: (1) wherein the scattergram is for example drawn taking the X-axis for fluorescence and the Y-axis for low-angle forward scattered light, as shown for instance in Fig. 8, distributing the cells by forming them in populations (i.e., clusters) according to maturation stage; then (2) using suitable analyzing software, setting these populations into population regions, and by analyzing counts of cells contained within these regions, computing the number and proportion of erythroblast in the maturation stages.
- [0052] The following examples will explain the foregoing and other objects, features, aspects and advantages of the present invention in further detail.

Example 1

- [0053] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
NK-2825	0.3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
BC-20TX [polyoxyethylene(20)cetyl ether]	3 g/l	Nikko Chemicals, Inc
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 30 mOsm/kg)		

- [0054] 1.0 ml of the Example 1 reagent was added to 30 μ l of anti-coagulant treated blood from a patient in whom erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 35°C for 10 seconds. Subsequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.
- [0055] Fig. 2 shows a scattergram in which the X-axis is taken for low-angle forward scattered light and the Y-axis for red fluorescence intensity. The blood cells form three populations: mononuclear leukocytes (lymphocytes, monocytes), granulocytes (neutrophils, eosinophils, basophils) and erythroblasts.

Example 2

- [0056] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
NK-321	0.3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
BC-16 [polyoxyethylene(16)oleyl ether]	3 g/l	Nikko Chemicals, Inc

(continued)

Ingredient	Quantity	Source
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 32 mOsm/kg)		

[0057] 1.0 ml of the Example 2 reagent was added to 30 μ l of anti-coagulant treated blood from a patient in whom erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 35°C for 10 seconds. Subsequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.

[0058] Fig. 3 shows a scattergram in which the X-axis is taken for low-angle forward scattered light and the Y-axis for red fluorescence intensity. The blood cells form three populations: mononuclear leukocytes (lymphocytes, monocytes), granulocytes (neutrophils, eosinophils, basophils) and erythroblasts.

Example 3

[0059] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
NK-1836	3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 25 mOsm/kg)		

[0060] 1.0 ml of the Example 3 reagent was added to 30 μ l of anti-coagulant treated blood from a patient in whom erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 35°C for 10 seconds. Subsequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.

[0061] Fig. 4 shows a scattergram in which the X-axis is taken for low-angle forward scattered light and the Y-axis for red fluorescence intensity. The blood cells form three populations: mononuclear leukocytes (lymphocytes, monocytes), granulocytes (neutrophils, eosinophils, basophils) and erythroblasts.

Example 4

[0062] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
DilCl (5)	3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 25 mOsm/kg)		

[0063] 1.0 ml of the Example 4 reagent was added to 30 μ l of anti-coagulant treated blood from a patient in whom

EP 1 004 880 A2

erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 35°C for 10 seconds. Subsequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.

[0064] Fig. 5 shows a scattergram in which the X-axis is taken for low-angle forward scattered light and the Y-axis for red fluorescence intensity. The blood cells form three populations: mononuclear leukocytes (lymphocytes, monocytes), granulocytes (neutrophils, eosinophils, basophils) and erythroblasts.

Example 5

[0065] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
Citric acid	10 mM	commercial product
NK-1836	0.3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 40 mOsm/kg)		

[0066] 1.0 ml of the Example 5 reagent was added to 30 µl of anti-coagulant treated blood from a patient in whom erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 35°C for 10 seconds. Subsequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.

[0067] Fig. 6 shows a scattergram in which the X-axis is taken for low-angle forward scattered light and the Y-axis for red fluorescence intensity. The blood cells form three populations: mononuclear leukocytes (lymphocytes, monocytes), granulocytes (neutrophils, eosinophils, basophils) and erythroblasts.

[0068] In analyzing the cytometric plots produced in the foregoing embodiments and illustrated in the corresponding drawings, a window was established for each population and cell counts and the cell ratios were calculated within the windows.

[0069] Fig. 7 is a correlation diagram displaying the results wherein a manual method (May-Grünwald-Giemsa Stain, 500 count) and a method according to the present invention were utilized.

Example 6

[0070] A reagent of the following composition was prepared.

Ingredient	Quantity	Source
salicylic acid	10 mM	commercial product
NK-2825	0.3 mg/l	Nippon Kandoh Shikiso Kenkyusho Co., Ltd.
LTAC [dodecyltrimethylammonium chloride]	0.3 g/l	Nikko Chemicals, Inc
purified water	1 l	
The pH was adjusted to 3.0 with NaOH. (Osmotic pressure: 40 mOsm/kg)		

[0071] 1.0 ml of the Example 6 reagent was added to 30 µl of anti-coagulant treated blood from a patient in whom erythroblasts had appeared in the peripheral circulation, and the preparation was reacted at 40°C for 5 seconds. Sub-

sequently fluorescence and low-angle forward scattered light were measured with a flow cytometer. The light source used was a 633 nm red semiconductor laser. The fluorescence measured was fluorescence of wavelength 660 nm or above.

[0072] Fig. 8 shows a scattergram in which the X-axis is taken for red fluorescence intensity and the Y-axis for low-angle forward scattered light. The blood cells form four populations: leukocytes, Stage I erythroblasts, Stage II erythroblasts, and Stage III erythroblasts. (Fig. 9 diagrams the corresponding distribution. NRBC: nucleated red blood cells, WBC: white blood cells, and ghosts.)

[0073] After performing a May-Grünwald-Giemsa stain on the Example 6 blood sample, visual observation was carried out with a microscope. The erythroblasts were discriminated into proerythroblasts, basophilic erythroblasts, polychromatophilic erythroblasts, and orthochromatophilic erythroblasts, and compared with the above-noted results obtained with the flow cytometer.

[0074] The table below shows the results from the flow cytometer and visual observation.


Present Invention		Visual Observation	
Stage I	0.7%	proerythroblasts + basophilic erythroblasts	0%
Stage II	17.6%	polychromatophilic erythroblasts	18%
Stage III	81.7%	orthochromatophilic erythroblasts	82.0%

[0075] From the table above, it is evident that the results of the present invention and of visual observation agree well.


[0076] In analyzing the cytometric plots produced in the in Example 6 and illustrated in Figs. 8 and 9, a window was established for each population and cell counts and the cell ratios were calculated within the windows.

Claims


1. Reagents for discriminating and counting erythroblasts in body fluid samples by flow cytometry, including at least one fluorescent dye selected from the group consisting of the following:




wherein R_1 , R_2 are either a hydrogen molecule, an alkyl group, an alkynyl group or an alkyl group substituted with a hydroxyl, Y, Z are either sulfur, oxygen, nitrogen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 and R_3 are a hydrogen molecule, a lower alkyl group or a lower alkoxy group, R_4 is a hydrogen molecule, an acyl group or an alkyl group, Z is sulfur, oxygen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;




wherein R_1 is a hydrogen molecule or a dimethylamino group, R_2 is an alkyl group, R_3 is a hydrogen molecule or a dimethylamino group, n is 1 or 2, and X^- is an anion;




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 is a dimethylamino group, R_3 is a hydrogen molecule or an amino group, R_4 is a hydrogen molecule, an alkyl group or an amino group, R_5 is a hydrogen molecule or a dimethylamino group, X^- is an anion, and Y is sulfur or oxygen;




wherein R_1 is a hydrogen molecule or a hydroxyl, R_2 , R_3 are a hydrogen molecule or a sulfonic group, and Y^+ is an alkali metal ion;




NK-2825;




NK-1836;




NK-1954;




Oxazine 750;




Cryptocyanine;




NK-376;




NK-382;




NK-2711;




NK-138;




Oxazine 720;




LDS730;




LD700;




Nile Blue A;



Brilliant Green;



Iodine Green; and




Malachite Green;

said reagents being selected to stain differentially leukocytes and erythroblasts in body fluid samples, wherein said fluorescent dye produces a difference detectable by flow cytometry in fluorescence intensity at least between leukocytes and erythroblasts.


2. Reagent as set forth in claim 1, further including a hemolytic agent for dissolving erythrocytes in a body fluid sample to an extent such that said hemolytic agent does not interfere with discrimination and counting by flow cytometry of erythroblasts in the body fluid sample, and such that said hemolytic agent conditions leukocytes and erythroblasts in the body fluid sample to be suitable for staining.
3. Reagent as set forth in claim 2, wherein the hemolytic agent is an aqueous solution having a pH of approximately 2.0 - 5.0 and an osmotic pressure of approximately 100 mOsm/kg or less.

EP 1 004 880 A2


4. Reagent as set forth in claim 3, wherein the hemolytic agent contains intramolecularly at least one of an organic acid having at least one aromatic ring, and a salt thereof.
5. Reagent as set forth in claim 4, wherein said organic acid is selected from salicylic acid, sodium salicylate and phthalic acid.
6. Reagent as set forth in claim 2, wherein the hemolytic agent is an aqueous solution containing surfactant in a concentration of approximately 10 to 10,000 mg/l.
7. Reagents as set forth in claim 6, the surfactant being selected from the group consisting of the following:




wherein R_1 , R_2 and R_3 either identically or differently are hydrogen atom, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_4 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and X^- is an anion;




wherein R_1 is a C_{8-18} alkyl group, and X^- is an anion;




wherein R_1 , R_2 either identically or differently are hydrogen atoms, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_3 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and n is 1 or 2;




wherein R_1 is a C_{9-25} alkyl group, alkenyl group or alkynyl group, R_2 is $-O-$,




or $-COO-$, and n is 10 to 40;




"MEGA-8";




sucrose monocaprate;




"Deoxy-BIGCHAP";




n-octyl-β-D-thioglucoside




n-nonyl-β-D-thiomaltoside;




n-heptyl- β -D-thioglucoside;



n-octyl- β -D-thioglucoside;



"CHAPS"; and



"CHAPSO";


wherein the surfactant enables flow cytometric discrimination and counting of erythroblasts in the body fluid samples by maturation stage.

8. Reagent as set forth in claim 1, wherein the body fluid samples are taken from one of the peripheral blood circula-


tion, bone marrow and urine of a human patient.

9. A method for discriminating and counting erythroblasts from body fluid samples by flow cytometry, comprising the step of:


assaying a body fluid sample flow cytometrically utilizing reagent selected to stain differentially leukocytes and erythroblasts in the body fluid sample, said reagent including at least one fluorescent dye selected from the group consisting of the following:




wherein R_1 , R_2 are either a hydrogen molecule, an alkyl group, an alkynyl group or an alkyl group substituted with a hydroxyl, Y, Z are either sulfur, oxygen, nitrogen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 and R_3 are a hydrogen molecule, a lower alkyl group or a lower alkoxy group, R_4 is a hydrogen molecule, an acyl group or an alkyl group, Z is sulfur, oxygen or carbon having a lower alkyl group, n is 0, 1 or 2, and X^- is an anion;



wherein R_1 is a hydrogen molecule or a dimethylamino group, R_2 is an alkyl group, R_3 is a hydrogen molecule or a dimethylamino group, n is 1 or 2, and X^- is an anion;




wherein R_1 is a hydrogen molecule or an alkyl group, R_2 is a dimethylamino group, R_3 is a hydrogen molecule or an amino group, R_4 is a hydrogen molecule, an alkyl group or an amino group, R_5 is a hydrogen molecule or a dimethylamino group, X^- is an anion, and Y is either sulfur or oxygen;



wherein R_1 is a hydrogen molecule or a hydroxyl, R_2 , R_3 are a hydrogen molecule or a sulfonic group, and Y^+ is an alkali metal ion;


5



10

NK-2825;


15



20

NK-1836;


25



30


NK-1954;

35



Oxazine 750;


40



45


Cryptocyanine;

50




NK-376;


55




NK-382;




NK-2711;




NK-138;




Oxazine 720;




LDS730;




LD700;




Nile Blue A;



Brilliant Green;



Iodine Green; and



Malachite Green;

wherein said fluorescent dye produces a difference detectable by flow cytometry in fluorescence intensity at least between leukocytes and erythroblasts.

10. A method for discriminating and counting erythroblasts as set forth in claim 9, further comprising the preparatory


steps of:

- (a) mixing the body fluid sample with a hemolytic agent selected for dissolving erythrocytes within body fluid samples to an extent that does not interfere with flow-cytometric assaying, and for conditioning leukocytes and erythroblasts to be suitable for staining; and
 (b) staining leukocytes and erythroblasts by mixing the sample as prepared in said step (a) with one of the fluorescent dyes for producing a difference detectable by flow cytometry in fluorescence intensity at least between leukocytes and erythroblasts;
 said method further comprising the steps of:
 (c) flow cytometrically assaying the sample as prepared in said step (b) by measuring at least one scattered light parameter and at least one fluorescence parameter; and
 (d) discriminating and counting erythroblasts utilizing intensity difference in scattered light and in fluorescence as measured in said step (c).


11. A method for discriminating and counting erythroblasts as set forth in claim 9, wherein the hemolytic agent is an aqueous solution having a pH of approximately 2.0 - 5.0 and an osmotic pressure of approximately 100 mOsm/kg or less.

12. A method for discriminating and counting erythroblasts as set forth in claim 11, further comprising the step of:


adding surfactant in a concentration of from approximately 10 to 10,000 mg/l to the hemolytic agent, wherein the surfactant is selected from the group consisting of the following:




wherein R_1 , R_2 and R_3 either identically or differently are hydrogen atoms, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_4 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and X^- is an anion;




wherein R_1 is a C_{8-18} alkyl group, and X^- is an anion;




wherein R_1 , R_2 either identically or differently are hydrogen atoms, C_{1-8} alkyl groups or C_{6-8} aralkyl groups, R_3 is a C_{8-18} alkyl group, C_{8-18} alkenyl group, or a C_{6-18} aralkyl group, and n is the integer 1 or 2;




wherein R_1 is a C_{9-25} alkyl group, alkenyl group or alkynyl group, R_2 is $-O-$.




or -COO-, and n is 10 to 40;




"MEGA-8";




sucrose monocaprate;




"Deoxy-BIGCHAP";




n-octyl- β -D-thioglucoside




n-nonyl- β -D-thiomaltoside;




n-heptyl- β -D-thioglucoside;



n-octyl- β -D-thioglucoside;



"CHAPS"; and



"CHAPSO."

- 30
- 35
- 40
- 45
- 50
- 55
13. A method for discriminating and counting erythroblasts as set forth in claim 12, further comprising the step of flow cytometrically assaying the sample mixed with the hemolytic agent including the surfactant, by measuring the at least one scattered light parameter and at least one fluorescence parameter for discriminating and counting erythroblasts in the body fluid sample by maturation stage.
 14. A method for discriminating and counting erythroblasts as set forth in claim 10, wherein the scattered light parameter is at least one selected from low-angle forward scattered light, high-angle forward scattered light, and orthogonal scattered light as a selected angle of scattered light received in the flow cytometric assay.
 15. A method for discriminating and counting erythroblasts as set forth in claim 13, wherein at least two erythroblast maturation stages are discriminated among erythroblasts in the body fluid sample.
 16. A method for discriminating and counting erythroblasts as set forth in claim 9, wherein the body fluid samples are taken from one of the peripheral blood circulation, bone marrow and urine of a human patient.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
05.02.2003 Bulletin 2003/06

(51) Int Cl.7: **G01N 33/50, G01N 33/58,
G01N 33/52, G01N 33/80**

(43) Date of publication A2:
31.05.2000 Bulletin 2000/22

(21) Application number: **98310004.1**

(22) Date of filing: **07.12.1998**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- **Sakata, Takashi**
Kakogawa-shi, Hyogo (JP)
- **Ikeuchi, Yoshiro**
Himeji-shi, Hyogo (JP)
- **Oguni, Shin'ichiro**
Kobe-shi, Hyogo (JP)

(30) Priority: **27.11.1998 JP 33691698**

(71) Applicant: **Sysmex Corporation**
Kobe-shi, Hyogo 651-0073 (JP)

(74) Representative: **Paget, Hugh Charles Edward et al**
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

(72) Inventors:
• **Tsuji, Tomohiro**
Himeji-shi, Hyogo (JP)

(54) **Erythroblast diagnostic flow-cytometry method and reagents**

(57) Reagents and a method for simple and rapid discrimination and counting of erythroblasts in peripheral blood or circulatory system-related samples accurately with high precision is disclosed. The reagents include a hemolytic agent for dissolving erythrocytes in a body fluid sample and for conditioning leukocytes and erythroblasts in the sample to be suitable for staining, and including at least one fluorescent dye selected to stain leukocytes and erythroblasts differentially. When the se-

lected fluorescent dye is mixed with the sample, a detectable difference in fluorescence intensity at least between leukocytes and erythroblasts arises under laser illumination in flow cytometric analysis. The reagents further include surfactant added to the hemolytic agent, selected to enable flow cytometric discrimination of erythroblasts in the body fluid sample by their maturation stages.

EP 1 004 880 A3

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 31 0004

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	EP 0 499 693 A (TOA MEDICAL ELECTRONICS) 26 August 1992 (1992-08-26)	1,8-16	G01N33/50 G01N33/58 G01N33/52 G01N33/80
Y	* claims; examples 1,2 *	2-7	
X	US 5 175 109 A (SAKATA TAKASHI ET AL) 29 December 1992 (1992-12-29)	1,8-16	
Y	* column 6; claims *	2-7	
	* column 4, line 37 - column 5, line 6 *		
	* column 10, line 55 - column 11, line 10 *		
Y	EP 0 806 664 A (TOA MEDICAL ELECTRONICS) 12 November 1997 (1997-11-12)	2-7	
	* claims; examples 1,2 *		
Y	EP 0 872 734 A (TOA MEDICAL ELECTRONICS) 21 October 1998 (1998-10-21)	4,5	
	* abstract *		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			G01N
-The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		18 September 2002	Vadot-Van Geldre, E
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1501 C1 12 (10/00)



European Patent
Office

Application Number

EP 98 31 0004

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet 8

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-16 partially

European Patent
OfficeLACK OF UNITY OF INVENTION
SHEET BApplication Number
EP 98 31 0004

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-16 partially
reagent comprising dye of formula 1 and method involving the use of such reagent
2. Claims: 1-16 partially
reagent comprising dye of formula 2 and method involving the use of such reagent
3. Claims: 1-16 partially
reagent comprising dye of formula 3 and method involving the use of such reagent
4. Claims: 1-16 partially
reagent comprising dye of formula 4 and method involving the use of such reagent
5. Claims: 1-16 partially
reagent comprising dye of formula 5 and method involving the use of such reagent
6. Claims: 1-16 partially
reagent comprising dye NK-2825 and method involving the use of such reagent
7. Claims: 1-16 partially
reagent comprising dye NK-1836 and method involving the use of such reagent
8. Claims: 1-16 partially
reagent comprising dye NK-1954 and method involving the use of such reagent
9. Claims: 1-16 partially
reagent comprising dye oxazine 750 and method involving the



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 98 31 0004

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

use of such reagent

10. Claims: 1-16 partially

reagent comprising dye cryptocyanine and method involving the use of such reagent

11. Claims: 1-16 partially

reagent comprising dye NK-376 and method involving the use of such reagent

12. Claims: 1-16 partially

reagent comprising dye NK-382 and method involving the use of such reagent

13. Claims: 1-16 partially

reagent comprising dye NK-2711 and method involving the use of such reagent

14. Claims: 1-16 partially

reagent comprising dye NK-138 and method involving the use of such reagent

15. Claims: 1-16 partially

reagent comprising dye oxazine 720 and method involving the use of such reagent

16. Claims: 1-16 partially

reagent comprising dye LDS730 and method involving the use of such reagent

17. Claims: 1-16 partially

reagent comprising dye LD700 and method involving the use of such reagent



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 98 31 0004

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

18. Claims: 1-16 partially

reagent comprising dye Nile Bleu A and method involving the use of such reagent

19. Claims: 1-16 partially

reagent comprising dye Brilliant Green and method involving the use of such reagent

20. Claims: 1-16 partially

reagent comprising dye of Iodine Green and method involving the use of such reagent

21. Claims: 1-16 partially

reagent comprising dye Malachite Green and method involving the use of such reagent

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 31 0004

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-09-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0499693	A	26-08-1992	JP 2927979 B2	28-07-1999
			JP 4268453 A	24-09-1992
			AU 648838 B2	05-05-1994
			AU 8774091 A	27-08-1992
			DE 69124595 D1	20-03-1997
			DE 69124595 T2	12-06-1997
			EP 0499693 A2	26-08-1992
			US 5298426 A	29-03-1994
US 5175109	A	29-12-1992	JP 1974296 C	27-09-1995
			JP 7006979 B	30-01-1995
			JP 63070167 A	30-03-1988
			JP 1906324 C	24-02-1995
			JP 6035972 B	11-05-1994
			JP 63134957 A	07-06-1988
			US 5928949 A	27-07-1999
			US 5296378 A	22-03-1994
			CA 1309327 A1	27-10-1992
			DE 3783838 D1	11-03-1993
			DE 3783838 T2	22-07-1993
			EP 0259833 A2	16-03-1988
			JP 1987131 C	08-11-1995
			JP 6011506 A	21-01-1994
			JP 7023890 B	15-03-1995
EP 0806664	A	12-11-1997	AU 712405 B2	04-11-1999
			AU 1777597 A	16-10-1997
			CA 2202207 A1	12-10-1997
			EP 0806664 A2	12-11-1997
			JP 10026620 A	27-01-1998
			TW 379284 B	11-01-2000
			US 5891731 A	06-04-1999
EP 0872734	A	21-10-1998	JP 10293131 A	04-11-1998
			CN 1197211 A	28-10-1998
			DE 69800581 D1	19-04-2001
			DE 69800581 T2	09-08-2001
			EP 0872734 A1	21-10-1998
			TW 390964 B	21-05-2000
			US 5968832 A	19-10-1999

EPO FORM P0455

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82